Ticker

ALTER.PA

Theradiag SA develops, manufactures, and markets in-vitro diagnostic products in France and internationally. The company offers LISA tracker, a tool for the monitoring of biotherapies; i-Tracker, a random access solution for therapeutic drug monitoring of biologics; i-Track10 for measurement of drug level and anti-drug antibodies; ez-Track 1 and ez-Tracker, a true point-of-care solution for therapeutic drug monitoring of biologics; and Immunotrol Tracker, a ready-to-use internal quality control sera for pharmacological dosage of biotherapies. It also provides autoimmune reagents for connective tissue diseases, rheumatoid arthritis, autoimmune liver diseases, vasculitis, celiac disease, anti-phospholipids syndrome, autoimmune thryroiditis, pernicious anemia, and other autoimmune diseases; IMMUNO-TROL, a multi-parametric precision control in autoimmunity; SQA-V system, a semen analyzer; V-Sperm for loading results, pictures, and videos of the samples into the computer; and rapid tests for colorectal cancer. In addition, the company offers instrumentation, including FIDIS system for simultaneous and specific detection of multiple analytes from the same sample in a single assay; and Theralis that integrates multiplex FIDIS immunofluorescence and ELISA. Theradiag SA was incorporated in 1986 and is based in Marne-la-Vallée, France. Theradiag SA operates as a subsidiary of Biosynex SA.